Targeting IL-2 to the endoplasmic reticulum confines autocrine growth stimulation to NK-92 cells

被引:41
作者
Konstantinidis, KV
Alici, E
Aints, A
Christensson, B
Ljunggren, HG
Dilber, MS
机构
[1] Karolinska Univ Hosp, Karolinska Inst, Div Hematol, Dept Med, SE-14186 Stockholm, Sweden
[2] Karolinska Univ Hosp, Karolinska Inst, Dept Med, Ctr Infect Med, SE-14186 Stockholm, Sweden
[3] Karolinska Univ Hosp, Karolinska Inst, Dept Lab Med, Div Pathol, SE-14186 Stockholm, Sweden
关键词
D O I
10.1016/j.exphem.2004.11.003
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Objective. Anti-tumor effects mediated by adoptively transferred natural killer (NK) cells are dependent on the presence of interleukin-2 (IL-2). IL-2 is considered to be a survival factor for NK cells and an enhancer of their cytotoxic potential. However, systemic administration of IL-2 is frequently impeded by undesirable side effects, such as high toxicity and nonlocalized administration. Genetic modification of NK cells expressing IL-2 in a localized and controlled manner could be a powerful tool for overcoming these obstacles. Methods. Consequently, we have cloned the IL-2 gene using PCR and designed constructs that target IL-2 to specific subcellular compartments. The IL-2-dependent NK-92 cell line was used to verify the functionality of the subcellularly targeted IL-2 constructs. Results. IL-2 targeted specifically to the endoplasmic reticulum (ER) was sufficient to support growth of NK-92 cells. In such cell lines, IL-2 was verified to be localized to the ER. IL-2 was not detected in the supernatant and growth of non-IL-2-modified NK-92 cells was not supported during coculturing experiments. IL-2-transduced NK-92 cell lines showed comparable functional activity and cytotoxicity to parental NK-92 cells. Conclusion. We demonstrate the ability of ER-retained IL-2 to provide autocrine growth stimulation to NK-92 cells, without secretion of the cytokine to the extracellular compartment. Therapy with IL-2 gene-modified autoactivating NK cells may avoid side effects imposed by exogenously administered IL-2. (C) 2005 International Society for Experimental Hematology. Published by Elsevier Inc.
引用
收藏
页码:159 / 164
页数:6
相关论文
共 36 条
[1]  
ARDIZZONI A, 1994, CANCER, V73, P1353, DOI 10.1002/1097-0142(19940301)73:5<1353::AID-CNCR2820730508>3.0.CO
[2]  
2-H
[3]   High-dose recombinant interleukin 2 therapy for patients with metastatic melanoma: Analysis of 270 patients treated between 1985 and 1993 [J].
Atkins, MB ;
Lotze, MT ;
Dutcher, JP ;
Fisher, RI ;
Weiss, G ;
Margolin, K ;
Abrams, J ;
Sznol, M ;
Parkinson, D ;
Hawkins, M ;
Paradise, C ;
Kunkel, L ;
Rosenberg, SA .
JOURNAL OF CLINICAL ONCOLOGY, 1999, 17 (07) :2105-2116
[4]   Natural killer cells in antiviral defense: Function and regulation by innate cytokines [J].
Biron, CA ;
Nguyen, KB ;
Pien, GC ;
Cousens, LP ;
Salazar-Mather, TP .
ANNUAL REVIEW OF IMMUNOLOGY, 1999, 17 :189-220
[5]   MECHANISM OF AUTOCRINE STIMULATION IN HEMATOPOIETIC-CELLS PRODUCING INTERLEUKIN-3 AFTER RETROVIRUS-MEDIATED GENE-TRANSFER [J].
BROWDER, TM ;
ABRAMS, JS ;
WONG, PMC ;
NIENHUIS, AW .
MOLECULAR AND CELLULAR BIOLOGY, 1989, 9 (01) :204-213
[6]  
Chada S, 2003, CURR OPIN MOL THER, V5, P463
[7]   Natural killer cell receptors: new biology and insights into the graft-versus-leukemia effect [J].
Farag, SS ;
Fehniger, TA ;
Ruggeri, L ;
Velardi, A ;
Caligiuri, MA .
BLOOD, 2002, 100 (06) :1935-1947
[8]   CARDIOPULMONARY TOXICITY OF ADOPTIVE IMMUNOTHERAPY [J].
GLAUSER, FL ;
DEBLOIS, G ;
BECHARD, D ;
FOWLER, AA ;
MERCHANT, R ;
FAIRMAN, RP .
AMERICAN JOURNAL OF THE MEDICAL SCIENCES, 1988, 296 (06) :406-412
[9]  
GONG JH, 1994, LEUKEMIA, V8, P652
[10]   Expansion of natural killer (NK) and natural killer-like T (NKT)-cell populations derived from patients with B-chronic lymphocytic leukemia (B-CLL): a potential source for cellular immunotherapy [J].
Guven, H ;
Gilljam, M ;
Chambers, BJ ;
Ljunggren, HG ;
Christensson, B ;
Kimby, E ;
Dilber, MS .
LEUKEMIA, 2003, 17 (10) :1973-1980